AEON Biopharma (AEON) Gains from Investment Securities (2021 - 2026)

AEON Biopharma has reported Gains from Investment Securities for 5 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Gains from Investment Securities rose 254.64% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$84.9 million (down 677.08% YoY) and the FY2025 annual result came in at -$84.9 million, down 677.04% from the prior year.
• Gains from Investment Securities grew to $1.0 million in Q4 2025 per AEON's latest filing, from $236000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $20.9 million in Q1 2024 and troughed at -$86.7 million in Q1 2025.
• A 5-year average of -$4.7 million and a median of -$657000.0 in 2024 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 14532.63% in 2024, down 1226.66% in 2024.
• Over 5 years, Gains from Investment Securities stood at -$1.1 million in 2021, then surged by 73.78% to -$291654.0 in 2022, then slumped by 446.2% to -$1.6 million in 2023, then surged by 58.76% to -$657000.0 in 2024, then soared by 254.64% to $1.0 million in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $1.0 million, $236000.0, and $542000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.